Preclinical studies of BB-1701, a HER2-targeting eribulin-containing ADC with potent bystander effect and ICD activity.
Yang WangBing XiaLixia CaoJianfeng YangCui FengFangdun JiangChen LiLixia GuYifan YangJing TianXin ChengKeiji FuruuchiJames FulmerArielle VerdiKatherine RybinskiAllis SotoEarl AlboneToshimitsu UenakaLikun GongTingting LiuQiuping QinZiping WeiYuhong ZhouPublished in: Antibody therapeutics (2024)
The preclinical data support the test of BB-1701 in patients with various HER2-expressing cancers, including those resistant to other HER2-targeting ADCs. A phase I clinical trial of BB-1701 (NCT04257110) in patients is currently underway.
Keyphrases
- data analysis
- growth factor
- clinical trial
- end stage renal disease
- ejection fraction
- chronic kidney disease
- cancer therapy
- recombinant human
- cell therapy
- peritoneal dialysis
- phase ii
- mesenchymal stem cells
- young adults
- machine learning
- patient reported outcomes
- drug delivery
- metastatic breast cancer
- diffusion weighted imaging
- patient reported